Researchers at UiO have tested a new device for delivering hormone treatments for mental illness through the nose. This method was found to deliver medicine to the brain with few side effects.
About one out of every hundred Norwegians develop schizophrenia or autism in the course of their lifetime. Moreover, at any one time some 20 000 people are receiving treatment for these problems. Many psychiatric disorders such as autism, schizophrenia and bipolar disorder are characterised by poor social functioning.
Oxytocin is a hormone that influences social behaviour and has shown promise for the treatment of mental illness.
Researchers at UiO have now discovered that low doses of oxytocin may help patients with mental illness to better perceive social signals. As part of this project, they have collaborated with the company OptiNose, who have developed a new device designed to improve medicine delivery to the brain via the nose.
Regulates social behaviour
Oxytocin has historically been known to play a crucial role in child rearing as it facilitates pregnancy, birth, and the release of milk during nursing. Further, oxytocin helps regulate cardiac functions and fluid levels. More recent research has revealed the importance of oxytocin for social behaviour.
Oxytocin is a neuropeptide and was discovered in 1953. Peptides are a group of molecules that consist of a chain of amino acids. Amino acids are also known as the building blocks of proteins, which we find in all types of cells. Oxytocin is produced in the hypothalamus, which is the brain’s coordinating centre for the hormone system.
Medicine through the nose
Because of oxytocin’s role in social behaviour, researchers have explored the possibility of administering the hormone for the treatment of mental illness. As oxytocin is a relatively large molecule, it has trouble crossing the barrier between the brain and circulating blood. Thus, researchers have administered oxytocin to patients through the nose as this route offers a direct pathway to the brain that bypasses this barrier.
However, researchers have a poor understanding of how oxytocin reaches and affects the brain. The most effective dose for treatment has also received little research attention.
Professor Ole A. Andreassen and his research team have collaborated with OptiNose on a project that evaluated two different doses of oxytocin and on how they affect the way in which social signals are perceived.
Low doses work best
Sixteen healthy men received two different doses of oxytocin, along with placebo. Volunteers were also given an intravenous dose of oxytocin, for a comparison of the effects of oxytocin in circulating blood. The research showed that only those administered a low dose of oxytocin experienced an effect on how they perceived social signals.
Professor Ole A. Andreassen explains:
“The results show that intranasal administration, i.e. introducing oxytocin through the nose, affects the function of the brain.
As no effect was observed after intravenous treatment, this indicates that intranasally administered oxytocin travels directly to the brain, as we have long believed.
The fact that we have shown the efficacy of a low dose of oxytocin on social perception is even more important.
A dose that is lower, but that still influences behaviour, will entail a lower risk of affecting other regulatory systems in the body. Very high doses of oxytocin could, in fact, have the opposite effect on social behaviour.”
The scientists also discovered that individuals with larger nasal cavities had a stronger response to a low dose of oxytocin.
OptiNose uses a new technology to distribute medicine to the brain, making use of the user’s breath to propel medicine deep into the nasal cavity.
Read more: Nasal spray device for mental illness
The Latest on: Oxytocin
via Google News
The Latest on: Oxytocin
- Billie Eilish Has Collaborated With Gucci On A Nail Art Collection And It’s Spiking Our Oxytocinon December 2, 2021 at 5:00 pm
If you've ever spent hours daydreaming about owning a set of towering nails like Billie Eilish, then wonder no more. With every beauty statement that the Grammy Award winner makes, her manicure—and ...
- FDA clears phase 2 study of nasal spray for chronic migraine reliefon December 1, 2021 at 12:58 pm
The spray, which consists of aerosolized oxytocin, was developed by Tonix Pharmaceuticals Holding Corp., a clinical stage biopharmaceutical company. Source: Adobe Stock “We are excited to have ...
- Oxytocin promotes social grooming in bonobos: testing the biobehavioural feedback loop hypothesison November 30, 2021 at 2:11 am
Oxytocin has attracted research attention due to its role in promoting social bonding. One notable recent hypothesis is the biobehavioral feedback loop, which posits that the oxytocin system has ...
- The European Oxytocin Market is scheduled to expand at over 8% value CAGR through 2030on November 24, 2021 at 3:00 am
ESOMAR certified consulting firm Future Market Insights (FMI) has recently published an exhaustive yet unbiased report on the global Oxytocin Market, highlighting the prominent parameters responsible ...
- Tonix Cleared to Propel Migraine Therapy into Phase IIon November 23, 2021 at 11:50 am
The Food and Drug Administration (FDA) has cleared the way for Tonix Pharmaceuticals to begin a Phase II study of its therapeutic candidate, which intends to prevent migraine headaches. Tonix expects ...
- How The Cofounders Of HigherDOSE Are Creating An Empire Of Wellness Productson November 23, 2021 at 10:19 am
When Lauren Berlingeri and Katie Kaps joined forces and launched HigherDOSE in 2016, it was conceptualized as a sauna experience like no other, featuring state-of-the-art infrared saunas. Find out how ...
- Tonix Pharmaceuticals Shares Rise 16% After FDA Clears IND Applicationon November 23, 2021 at 9:34 am
A related intranasal potentiated oxytocin product candidate, TNX-2900, is under development for the treatment of Prader-Willi syndrome. Write to Chris Wack at [email protected] We sell different ...
- FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraineon November 23, 2021 at 5:40 am
Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine. TNX-1900 is intranasal potentiated oxytocin designed for the prevention of migraine headaches in chronic ...
- Oxytocin Gene Methylation and Brain Development Impacted by Child Abuseon November 22, 2021 at 5:10 am
Smit, PhD, from Emory University. The hormone in question is oxytocin, which plays a key role in the capacity to feel empathy and love, and learn prosocial behaviors like bonding. The biological ...
via Bing News